ACT logo

AlzChem Group AG Stock Price

XTRA:ACT Community·€1.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 61 Fair Values set on narratives written by author

ACT Share Price Performance

€175.00
15.60 (9.79%)
€204.49
Fair Value
€175.00
15.60 (9.79%)
14.4% undervalued intrinsic discount
€204.49
Fair Value
Price €175.00
AnalystConsensusTarget €204.49
AnalystHighTarget €200.00
AnalystLowTarget €177.00

ACT Community Narratives

·
Fair Value €204.49 14.4% undervalued intrinsic discount

ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation

3users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
·
Fair Value €253.97 31.1% undervalued intrinsic discount

Rising Global Protein Demand Will Fuel Sustainable Specialty Chemicals

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value €177 1.1% undervalued intrinsic discount

Rising Environmental Mandates And Input Costs Will Squeeze Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€177
1.1% undervalued intrinsic discount
Revenue
9.49% p.a.
Profit Margin
13.14%
Future PE
20.64x
Price in 2029
€202.08

Trending Discussion

No trending discussion available.

Updated Narratives

ACT logo

ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows

Fair Value: €253.97 31.1% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ACT logo

ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook

Fair Value: €204.49 14.4% undervalued intrinsic discount
24 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ACT logo

ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend

Fair Value: €177 1.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
3 Rewards

AlzChem Group AG Key Details

€581.1m

Revenue

€195.3m

Cost of Revenue

€385.9m

Gross Profit

€319.0m

Other Expenses

€66.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
6.60
66.40%
11.50%
0%
View Full Analysis

About ACT

Founded
1908
Employees
1680
CEO
Andreas Niedermaier
WebsiteView website
www.alzchem.com

AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silicon nitride for ceramics; and photovoltaic modules in the solar industry. The Basics & Intermediates segment produces raw materials for specialty chemicals; and products for agriculture and metallurgy, as well as intermediates for the chemical industry that are produced from lime, carbon, and electricity. This segment also engages in the production and sale of guanidine salts as a raw material for agrochemicals and active pharmaceutical ingredients. The Other & Holding segment provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. It offers products and services to agricultural sector under the CALCIUM CYANAMIDE PERLKA, EMINEX, DORMEX, ALZOGUR, SITOFEX, and BREAK-THRU brands; animal nutrition sector under the CREAMINO brands; human nutrition sector under the CREAPURE, CREAVITALIS, LIVADUR, and ALIPURE brands; pharma sector under the GUANIDINE SALTS – BIOSELECT brand; fine chemicals sector under the GUANIDINSALZE -BIOSELECT, CYANAMIDE, DICYANDIAMIDE, GUANAMINE, NITRILES, MELFLOCK and ALZOFIX, THIOUREA, and NITROGUANIDINE brands; metallurgy sector under the CAD, CALCIPRO, and CALZOT brands, as well as technical gases and calcium carbide; renewable energy sector under the DYHARD and SILZOT brands; and custom synthesis, such as toll micronization and manufacturing. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.

Recent ACT News & Updates

Narrative Update Jul 07

ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook

The analyst price target for AlzChem Group has increased from €192.07 to €204.49, with analysts citing the company's unique position in the calcium carbide and calcium cyanide value chain, along with recent supportive research, as key factors behind the revision. Analyst Commentary Recent research coverage on AlzChem Group highlights a mix of supportive and cautious views as analysts reassess where the stock should trade, with an emphasis on the company’s role in the calcium carbide and calcium cyanide value chain and how effectively it can convert that position into sustainable execution.
Narrative Update Jun 23

ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend

Analysts have lifted their price target on AlzChem Group by €4, from €173 to €177, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, as well as updated assumptions on discount rate, revenue growth, profit margin and forward P/E. Analyst Commentary Recent research on AlzChem Group highlights the company’s role in the calcium carbide and calcium cyanide value chain, but not all commentary is upbeat.

Recent updates

No updates